Latest News
Week ahead: US Q2 GDP, Fed meeting in focus
Financial markets' focus over the coming week will be second quarter gross domestic product readings out of Germany and the US, on Wednesday and Friday, respectively.
US close: Stocks snap losing streak amid continued stimulus talks
US stocks closed higher on Monday as market participants prepared for a week full of major corporate earnings amid continued stimulus talks in Washington.
Tuesday preview: UK retail sales, St.James's Place in the spotlight
Investor focus on Tuesday will be on the global consumer as the Confederation of British Industry releases its Distributive Trades survey for July.
Europe close: Coronavirus worries weigh on stocks
Stocks in Europe traded slightly lower on Monday, weighed down by concerns around a possible second wave of Covid-19 infections, particularly in Spain, and ongoing tensions between China and the US.
London close: Stocks finish weaker on Covid travel concerns
London stocks finished in the red despite a late rally on Monday, as a strong showing from precious metals miners helped to offset weakness in the travel sector, after Ryanair warned over a second wave of coronavirus infections.
Director dealings: WH Ireland chair makes share purchase
WH Ireland revealed on Monday that chair Philip Shelley had acquired 124,997 ordinary shares in the AIM-listed investment manager.
Broker tips: FirstGroup, Tate & Lyle, Indivior
Analysts at Canaccord Genuity upgraded their stance on transport operator FirstGroup from 'hold' to 'buy' on Monday but noted that timing remained uncertain despite the firm's good value.
Google to keep employees working from home until July 2021
Tech behemoth Alphabet will keep Google employees working from home until at least July 2021, making it the first major US corporation to formalise an extended return to work timetable as a result of the Covid-19 pandemic.
Cora Gold shares soar on new discovery at Sanankoro
West Africa-focussed gold company Cora Gold announced the discovery of a new 1. 5 kilometre gold zone at its flagship Sanankoro Gold Project in Mali on Monday.
US open: Stocks open higher in first session of earnings packed week
US stocks opened higher on Monday as market participants prepared for a week full of major corporate earnings amid continued stimulus talks in Washington.
FTSE 250 movers: Travel shares take a hit; Kainos rallies
London’s FTSE 250 was down 0. 3% at 17,206. 50 in afternoon trade on Monday.
E-highways could cut CO2 emissions dramatically by 2030s
The UK could cut the majority of the CO2 emissions generated by traffic by installing e-highways in a project that would pay for itself within 15 years and cost around £20bn, a think-tank said.
Deutsche Bank to quit coal mining projects by 2025
Deutsche Bank said on Monday that it will wind down its worldwide coal mining operations by 2025 at the latest.
Oilex makes 'substantial progress' towards restarting at Pendalian
Oilex said on Monday that “substantial progress” has been made towards its objective to regain a participating interest in the West Kampar production sharing contract (PSC) in Indonesia.
ImmuPharma clears 'important' regulatory hurdle for Lupuzor trial
Specialist drug discovery and development company ImmuPharma announced what it called “an important regulatory milestone” on Monday, in preparation for the new optimised international phase 3 trial of ‘Lupuzor’ for the autoimmune disease systemic lupus erythematosus.
Canaccord Genuity upgrades FirstGroup to 'buy'
Analysts at Canaccord Genuity upgraded their stance on transport operator FirstGroup from 'hold' to 'buy' on Monday but noted that timing remained uncertain despite the firm's good value.
FTSE 100 movers: Gold miners shine; travel stocks slump
London’s FTSE 100 was down 0. 3% at 6,103. 93 in afternoon trade on Monday.
US durable goods orders print slightly below forecasts in June
Orders for goods made to last more than three years continued to bounce back last month, despite another sharp drop in orders for civilian aircraft.
Moderna starts dosing patients for phase III Covid-19 vaccine clinical trial
Moderna has started to dose patients in its 30,000-strong phase three clinical trial of its Covid-19 vaccine candidate, mRNA-1273.
Important Legal Notice about News Sources: Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news and we may not share the views of the author or publisher. We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.
The value of investments can fall and you may get back less than you invested.